期刊文献+

危重患者血小板活化标志物CD_(62)P、PAC-1的临床观察 被引量:2

下载PDF
导出
摘要 目的研究危重患者的血小板活化标志物P-选择素(CD62P)、血小板膜糖蛋白Ⅱb/Ⅲa(PAC-1)的变化。方法 68例患者根据全身炎症反应综合征(SIRS)和多脏器功能不全(MODS)诊断标准,将患者分为无SIRS组、SIRS组和MODS组。应用APACHEⅡ评分系统分别评分;应用HEMACELL Plus全自动血细胞分析仪通过阻抗法进行血小板的计数;应用流式细胞仪分别检测3组CD62P、PAC-1。结果无SIRS组、SIRS组、MODS组患者CD62P、PAC-1随病情加重,绝对值逐渐增加3,组比较差异有统计学意义(P均<0.01)。结论动态监测危重患者CD62 P、PAC-1水平均可反映危重患者的病情变化。
出处 《山东医药》 CAS 北大核心 2011年第4期83-84,共2页 Shandong Medical Journal
  • 相关文献

参考文献7

二级参考文献56

  • 1代平,余思忠,叶发贵.急诊重度创伤结局的ASCOT法预测研究[J].中国医药导报,2006,3(23):30-31. 被引量:1
  • 2凌锋,焦力群,代表国家"十五"医学攻关脑卒中规范化外科治疗技术推广应用研究课题组.颈动脉内膜剥脱术与支架成形术对颈动脉粥样硬化性狭窄治疗的初步研究[J].中国脑血管病杂志,2006,3(1):4-8. 被引量:60
  • 3谭勇明,韦赤勇,邓树荣.危重病患者血小板与血糖变化的临床价值探讨[J].广西医学,2007,29(2):187-189. 被引量:4
  • 4包承鑫.血小板的生物化学性能和分子生物学:血小板功能[M].//张之南,杨天楹,郝玉书.血液病学(下册).北京:人民卫生出版社,2003:1527-1534,1530-1532.
  • 5Hiroshi O, Satoshi G, Toshiaki I,et al. SIRS - associated coagulopathy and organ dysfunction in critically ill patient with thrombocytopenia[J]. Shock, 2007, 28(4) : 411 -417.
  • 6Yaguchi A, Lobo FL, Vincent JL, et al. Platelet function in sepsis [J]. Thromb Haemost,2004,2(12) :2096 -2102.
  • 7Warkentin TE,Aird WC, Rand JH. Platelet. Endothelial interactions: sepsis, HIT, and antiphospholipid syndrome [ J ]. Hematology, 2003, 2003(2) :497 -518.
  • 8Philipp v H, Christian W. Platelets as immune cells bridging inflammation and cardiovascular disease [J]. Circulation Research, 2007, 5(19) :27 -40.
  • 9Strauss R, Wehler M, Mehler K,et al. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome [ J ] . Crit Care Med, 2002, 30 ( 8 ) : 1765 - 1771.
  • 10Serdar A, Philip HM, Arnaldo de M, et al. Time course of platelet counts in critically ill patients [J]. Crit Care Med,2002,30( 4): 753 - 757.

共引文献47

同被引文献19

  • 1Provan D, Stasi R, Newland AC, et al. International consensus re- port on.the investigation and management of primary immune throm- bocytopenia [ J ]. Blood, 2010,115 (2) : 168-186.
  • 2Cines DB, Blanehette VS. Immune thrombocytopanic purpura[ J]. N Engl J Med, 2002,346 ( 13 ) :995-1008.
  • 3McEver RP. Seleetins [ J]. Curr Opin Immunol, 1994,6 ( 1 ) : 75-84.
  • 4Hayashi S, Oshida M, Kiyokawa T, et al. Determination of activa- ted platelets : evaluation of methodology and application for patients with idiopathic thrombocytopenie pnrpura [ J ]. Rinsho Byori, 2001,49(12) :1287-1292.
  • 5Terrell DR, Beebe LA, Vesely SK, et al. The incidence of im- mune thrombocytopenic purpura in children and adults: a critical review of published reports [ J ]. Am J Hematol, 2010,85 ( 3 ) : 174-180.
  • 6Johnsen J. Pathogenesis in immune thrombocytopenia: new insights [J]. Hematology Am Soc Hematol Educ Program, 2012 (2012) : 306-312.
  • 7Sherernata WA, Jy W, Horstman LL, et al. Evidence of platelet activation in multiple sclerosis [ J ~. J Neuroinflammation, 2008 (5) :27.
  • 8Shattil S J, Cunningham M, Hoxic JA. Detection of activated plate- lets in whole blood using activation-dependent monoelonal antibod-ies and flow cytometry[ J]. Blood, 1987,70(1 ) :307-315.
  • 9Zhou B, Zhao H, Yang RC, et al. Multi-dysfunctional pathophysi- ology in ITP[J]. Crit Rev Oncol Hematol, 2005, 54 (2): 107-116.
  • 10POLEK A, SOBICZEWSKI W, MATOWICKA -KARNA J. P -se- lectin and its role in some diseases [ J ]. Postepy Hig Med Dosw; 2009, 63(10): 485 -470.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部